About mirikizumab
Interleukin-23 p19 monoclonal antibody
Used for
- Treats moderately to severely active ulcerative colitis in adults.
- Treats moderately to severely active Crohn’s disease in adults.
Usual adult dose
Ulcerative colitis: 300 mg intravenously at weeks 0, 4, and 8, then 200 mg under the skin every 4 weeks. Crohn’s disease: 900 mg intravenously at weeks 0, 4, and 8, then 300 mg under the skin every 4 weeks.
Common side effects
- Upper respiratory infections
- Headache
- Injection-site reactions
- Joint pain
Important warnings
- Screen for tuberculosis before treatment; treat latent infection first.
- Avoid live vaccines during treatment.
- Serious infections can occur; treatment may need to stop during severe infection.
- Rarely, liver injury occurs; monitoring may be needed.
Pregnancy
Human pregnancy information is limited. Use during pregnancy only when clinically justified; discuss risks with a healthcare professional.
Breastfeeding
It is unknown whether mirikizumab passes into breast milk. Consider breastfeeding benefits alongside treatment needs.
Interactions
- Avoid live vaccines during treatment.
- Tell clinicians about all medicines and vaccines; other immune-suppressing treatments may increase infection risk.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.